© Copyright 2008-2026 Synerphysics, Inc. All rights reserved. Dillon Capital Strategies is an operating unit of SynerPhysics, Inc.
Joseph S. Dillon, PH.D., MBA
President, Dillon Capital Strategies
Joseph S. Dillon, Ph.D., MBA, is President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 30 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology valuations. Dr. Dillon has screened thousands of opportunities, valued over 450 deals and has been in a lead role for nearly 50 closed transactions with a combined value approaching $25 billion. Since forming Dillon Capital Strategies, Dr. Dillon has consulted dozens of companies and held interim senior positions, including CEO, CFO, and Head of BD at select clients. Dr. Dillon also provides specialized, strategic and transaction focused training for biopharma professionals. Prior to this, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Cerner). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center (sold to AAI), a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company (IPO, then sold to US Bancorp); CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a Ph.D. in Theoretical Physics/Metaphysics, an M.B.A. in International Finance, and a bachelor’s degree in Finance.
© Copyright 2017 Synerphysics, Inc. All rights reserved. Dillon Capital Strategies is
an operating unit of Synerphysics.
Vision, Planning, Action
Joseph S. Dillon, PH.D., MBA
President, Dillon Capital Strategies
Joseph S. Dillon, Ph.D., MBA, is President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 30 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology valuations. Dr. Dillon has screened thousands of opportunities, valued over 450 deals and has been in a lead role for nearly 50 closed transactions with a combined value approaching $25 billion. Since forming Dillon Capital Strategies, Dr. Dillon has consulted dozens of companies and held interim senior positions, including CEO, CFO, and Head of BD at select clients. Dr. Dillon also provides specialized, strategic and transaction focused training for biopharma professionals. Prior to this, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Cerner). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center (sold to AAI), a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company (IPO, then sold to US Bancorp); CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a Ph.D. in Theoretical Physics/Metaphysics, an M.B.A. in International Finance, and a bachelor’s degree in Finance.
